Mar 12, 2026 7:30am EDT Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study
Mar 6, 2026 7:47am EST Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
